Kornimate/medical-research-clean huggingface dataset:
the effect of anxiety on perioperative pain: patient and provider perception

Conditions: Pain

Summary: in this study we will assess the incidence and severity of intraoperative and postoperative pain and determine the effect of preoperative anxiety on intraoperative and postoperative pain incidence. secondary outcome is to assess provider perception of pain.

this is a prospective, observational study. following obtaining written formal consent parturients will be requested to fill out the following questionnaires 1. three questions to predict acute pain: * verbal numeric score anxiety 0-10 * anticipated postoperative pain level * anticipated analgesic requirements 2. speilberger state-trate inventory index 3. pain catastrophizing scale in the post anesthesia care unit (pacu) parturients will be approached and requested to fill out a questionnaire regarding intraoperative pain, medication consumption, anxiety and nausea. furthermore parturients will also be approached at 12 hours and 48 hours postpartum and questioned regarding anxiety levels and medication consumption and requested to fill out the obsqor 11 questionnaire at 12 hours postpartum. additionally, both the attending anesthesiologist and obstetrician will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.

Eligibility criteria:
inclusion criteria: \*women undergoing an elective cesarean section under spinal anesthesia with the ability to comply with the study requirements will be eligible for participation exclusion criteria: * all women unable to receive spinal anesthesia or with inadequate spinal anesthesia prior to the beginning of surgery (less than t4 sensory level to pinprick assessed from blunt tip needle in caudal to cranial direction ) * all women receiving antianxiety medication * language barrier
a single-dose study to investigate the effects of 3 different doses of inhaled azd2115 in copd patients

Conditions: COPD

Summary: this study in copd patients will investigate the bronchodilatory effect of azd2115. azd2115 will be tested versus placebo and active comparators. the safety and tolerability of azd2115 including investigations of clinically relevant systemically mediated effects will also be investigated.

a randomised, double-blind, placebo and active controlled, multi-centre, 6 way cross-over, single-dose phase iia study to investigate the local and systemic effects of 3 different doses of inhaled azd2115 in patients with chronic obstructive pulmonary disease (copd)

Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study specific procedures * male or female of non-childbearing potential (post-menopausal or surgically sterilised), age ≥40 years at visit 1 * clinical diagnosis of copd for more than 1 year at visit 1, according to gold guidelines * post-bronchodilator fev1 ≥ 40 to \< 80% of the predicted normal value and post-bronchodilator fev1/fvc \< 70% * reversible airway obstruction exclusion criteria: * significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the result of the study, or the patient's ability to participate in the study. * an exacerbation of copd within 6 weeks prior to visit 1 * treatment with systemic glucocorticosteroids with 6 weeks of visit 2. * recent or ongoing respiratory tract infection during enrolment period. * need for long-term oxygen therapy and/or saturation o2 \< 92%.

Keywords: copd, pulmonary disease
safety, tolerability, and efficacy of gs-9876 in participants with active rheumatoid arthritis on background therapy with methotrexate

Conditions: Rheumatoid Arthritis

Summary: the primary objective of this study is to evaluate the effect of gs-9876 versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (ra) in participants with active ra as measured by change from baseline in disease activity score for 28 joint count using c-reactive protein (crp) (das28 (crp)) at week 12.


Eligibility criteria:
key inclusion criteria: * active ra disease as defined by: a tender joint count (tjc) of ≥ 6 (out of 68), a swollen joint count (sjc) of ≥ 6 (out of 66) at screening and day 1 * inadequate response to treatment with oral or parenteral methotrexate (mtx) 7.5 to 25 mg/week continuously for at least 12 weeks * no evidence of active or latent tuberculosis key exclusion criteria: * prior treatment with b-cell depleting agents (eg, rituximab), unless more than 6 months prior to the first dose of study drug and documented return of cd19+ cells at screening * prior treatment with any commercially available or investigational spleen tyrosine kinase (syk) inhibitor * concurrent treatment with any other conventional synthetic dmard (csdmard) other than mtx and/or hydroxychloroquine (hcq) (prior csdmard treatment allowed if appropriate wash out as defined in the protocol) * concurrent treatment with any biological disease modifying anti-rheumatic drug (bdmard)(prior bdmard treatment allowed if appropriate wash out as defined in the protocol). prior failure to treatment with bdmards is not an exclusion criterion. note: other protocol defined inclusion/ exclusion criteria may apply.
vitamin e supplementation for children with transfusion dependent beta thalassemia on different iron chelation regimen

Conditions: Beta-Thalassemia

Summary: repeated transfusions are the mainstay of disease management in most patients with transfusion dependent beta thalassemia.iron overload predispose to oxidative stress and tissue injury. oxidative stress play important role in pathogenesis of anemia in beta thalassemia. vitamin e is often depleted in thalassemia patients.

oxidative stress status is very important in thalassemic patients and explains the different manifestations in thalassemic patients. vitamin e is fat soluble vitamin shown to reduce the oxidative stress in thalassemia and to reduce lipid peroxidation of red cell membranes. therefore, this study shows the safety of oral vitamin e as adjuvant therapy to three iron chelators : desferoxamine,deferiprone and deferasirox in moderately iron overloaded children and adolescents with transfusion dependent beta thalassemia and its relation to iron overload over one year.

Eligibility criteria:
inclusion criteria: * beta thalassemia patients on regular packed red blood cells transfusion,with vitamin e deficiency * serum ferritin 1000-2500 ug/l * cardiact2\*\>10ms and ejection fraction \>55% exclusion criteria: * diabetes,active hepatitis(serum transaminases \>2 times uln) * renal impairment (serum creatinine\>2times uln) * participation in previous investigational drug study with 3 months preceding screening supplementation with antioxidants or vitamins within 3 months prior to the study and patients with known allergy to vitamin

Keywords: thalasssemia vitamin e oxidative stress
carmustine plus o6-benzylguanine in treating patients with recurrent or progressive glioma

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combining carmustine and o6-benzylguanine in treating patients who have recurrent or progressive glioma.

objectives: i. determine the activity of carmustine and o6-benzylguanine in patients with recurrent or progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma resistant to nitrosourea. ii. determine the toxic effects of this regimen in these patients. outline: patients receive o6-benzylguanine iv over 1 hour, followed 1 hour later by carmustine iv over 1 hour on day 1. treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 18-32 patients will be accrued for this study within 12-18 months.

Eligibility criteria:
disease characteristics: histologically confirmed recurrent or progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma resistant to nitrosourea (defined as progressive or recurrent disease within 8 weeks of receiving nitrosourea) measurable residual disease by mri or ct scan patient characteristics: age: 18 and over performance status: karnofsky 60-100% life expectancy: not specified hematopoietic: absolute granulocyte count at least 1,500/mm3 platelet count at least 100,000/mm3 hemoglobin greater than 10 g/dl hepatic: bilirubin normal sgot no greater than 2.5 times upper limit of normal renal: creatinine no greater than 1.5 mg/dl bun no greater than 25 mg/dl pulmonary: dlco greater than 80% predicted other: not pregnant or nursing fertile patients must use effective contraception during and for 2 months after study prior concurrent therapy: biologic therapy: not specified chemotherapy: see disease characteristics at least 4 weeks since prior chemotherapy at least 6 weeks since prior nitrosourea, procarbazine, or mitomycin and recovered no prior nitrosourea greater than 1,200 mg/m2 endocrine therapy: concurrent stable dose corticosteroids allowed if on for at least two weeks prior to study radiotherapy: at least 4 weeks since prior radiotherapy surgery: not specified

Keywords: recurrent adult brain tumor adult glioblastoma adult anaplastic astrocytoma adult mixed glioma adult giant cell glioblastoma adult gliosarcoma
recovery napping protocol for anesthesiologist performance

Conditions: Sleep Deprivation; Critical Incident; Sleep; Anesthesia

Summary: sleep deprivation impacts performance of shift workers in health care. anesthesiologists are a population at risk that endures stressful situations and changing working hours. the decreased performance could be the cause for undesirable events. power-napping is known to be an efficient technique to mitigate the detrimental effects of sleep deprivation and is a feasible measure to implement in critical care units. still there are few insights that measure the clinical relevance in the field. with the high-fidelity simulations this study is able to measure clinical performance and test for those effects. therefore we propose a prospective, monocentric study to evaluate a power-napping protocol (less than 30min)

residents in anesthesiology will be recruited on voluntary basis. they will pass the high fidelity simulation twice, once as a baseline measure under normal conditions after a typical night at home and once sleep deprived after a night shift. baseline participants will wear actigraphy bracelets to define their sleep pattern for 2 weeks, then they will spent a normal night at home before coming to the performance center in the afternoon (13h to18h). there they will respond to questions about stress and sleep, will be equipped with smart shirts (hexoskin) to measure their level of stress during the performance, and then undertake a crisis simulation. afterwards they pass some standardized cognitive tests. training the whole year group of residents will be trained to understand sleep management and learn power napping. after the workshop they will individually be trained during 2 weeks including some follow up calls. intervention the participants carry again actigraphy bracelets. then they work a night shift in their service where they usually sleep less than four hours. the morning after the shift participants are free to spend how the like while sleep is being controlled with actigraphy bracelets. in the afternoon (13 to 18h) they return for the second time to the performance center. they are randomly assigned to a napping or non napping group and equipped with ambulatory ecg (hexoskin) as well es ambulatory eeg (somfit). after the intervention period (nap or leisure time) they proceed with the same performance measures as at baseline including a simulation crisis and computerized cognitive tests.

Eligibility criteria:
inclusion criteria: * second to fifth year of residency * completing night shifts at anesthesia/reanimation unit exclusion criteria: * no consent

Keywords: power-napping high fidelity simulation night shift clinical performance
study to help understand the action of the drug etanercept for the adult patient with psoriasis

Conditions: Psoriasis

Summary: the investigator's laboratory is studying a skin disease known as psoriasis. the purpose of this protocol is to study the action and the effects of etanercept, on psoriasis. this medication has been studied extensively and has been found to be effective and safe in the treatment of psoriasis. the eligible patient will have 10% of his/her body surface area involved with psoriasis vulgaris. this trial is a phase iii study to help understand the action of the drug etanercept, trade name enbrel, for the adult patient with moderate to severe plaque psoriasis and who is a candidate for internal medications.

the eligible patient will receive the drug etanercept (enbrel), and will self inject with etanercept twice a week for the first 12 weeks. the patient will be taught to self inject the medication at home and will be seen in the clinic weekly, for the first four weeks and then once a month. during the second 12 weeks of the study, patients will be placed in one of two groups by the drug company participating. one group of patients will be randomized to either continue receiving the medication and will self inject once a week. a second group will be randomized to not receive the medication but will continue to be followed and examined at monthly visits. the drug company will do the randomization or choice of group, and each patient has a one in two chance of being placed in one group or the other. at the clinic visits, the patient can expect that a physical exam and skin exam will be done. at specific weeks, blood work will be drawn, clinical photography taken and a skin biopsy done. two types of skin biopsies will be done after local anesthesia has been administered. one is a punch biopsy where a small piece of skin will be taken, the approximate size of a pencil eraser. the second type of skin biopsy is a shave biopsy, where a postage sized piece of skin will be taken.

Eligibility criteria:
inclusion criteria: * gender: male and female * minimum age: 18 * maximum age: 70 exclusion criteria: * healthy volunteers
oral symptoms of covid-19 among infected medical doctors

Conditions: COVID-19 Respiratory Infection

Summary: oral symptoms of corona virus disease have been reported by many studies. the lack of direct contact between the dentist and the patient during the active disease presented an obstacle to build a strong body of evidence. the aim of the study is to report the oral symptoms of covid-19 and correlate the occurrence of these symptoms with various disease-related factors.

this is a cross-sectional web-based survey targeted medical doctors infected with covid-19. the survey questioned the diagnosis of the disease, the severity of the disease, the general symptoms, the oral symptoms along with drug and medical history. the survey comprised a total of 3 main sections. the first section included demographic data and diagnostic method for covid-19 infection. the second section included question about duration of the disease, the general manifestations of the disease, the previous medical history. history of smoking, severity of covid-19 infection and history of hospitalization. drug history and treatments for covid-19. presence of blood discrepancies during covid-19 infection. the third section targeted detailed oral manifestations of the disease and questions about the oral hygiene and presence of previous oral lesions. the questions about oral manifestations were designed based on a systematic search through the current literature, dated between 2019 and january 2021.

Eligibility criteria:
inclusion criteria: * covid-19 infection * medical doctors exclusion criteria: * none

Keywords: covid-19 dysgeusia xerostomia
acute effect of passive joint mobilization in non-specific neck pain

Conditions: Neck Pain

Summary: aim of present study is investigating the acute effects of passive joint mobilization on pain perception and range of motion. study protocol includes passive joint mobilization application to study group with neck pain and blood sample collection of study and healthy control group.

our purpose of planning this study is to examine the acute effect of passive joint mobilization application on pain perception and range of motion in women with non-specific neck pain. the hypotheses we will test for this purpose; h1- passive joint mobilization application increases the range of motion of the cervical joint in women with non-specific neck pain. h2- passive joint mobilization application increases the pressure pain threshold in women with non-specific neck pain. h3- passive joint mobilization increases serum orexin a and neurotensin levels in women with non-specific neck pain.

Eligibility criteria:
inclusion criteria: for intervention group; * having neck pain lasting more than 30 days and being diagnosed with non-specific neck pain * having obtained 14/50 points and above in neck disability index * expressing neck pain at least 34/100 points and above on a visual analog scale * being 20-45 years old and female for healthy control group; - healthy volunteers without a chronic illness and musculoskeletal pain exclusion criteria: * congenital anomalies * previously diagnosed orthopedic diseases related to the spine * pregnancy and having just given birth * within the last 3 months; use of corticosteroids, cytotoxic drugs, or immunosuppressants * liver or kidney failure * acute or chronic infections (including hiv) * serious pathologies (such as cancer, spondylolisthesis, rheumatoid arthritis or ankylosing spondylitis) * symptoms of cervical spinal stenosis (such as incoordination of hands, arms and legs, bowel and bladder incontinence) * radix compression (such as sensory changes, muscle weakness or decreased reflexes) * whiplash or a history of cervical surgery

Keywords: non-specific neck pain passive joint mobilization blood markers neck range of motion
exparel v dexamethasone in rcr

Conditions: Rotator Cuff Tears; Postoperative Pain

Summary: effective and safe control of pain after shoulder surgery is an important component of the post-surgical process. patients who are comfortable in the early period after surgery are more satisfied with their experience and are better able to participate in rehabilitation exercises during their stay in the hospital. as surgeons and health care systems in the united states find themselves in the middle of an opioid epidemic, it is necessary to discover different options to provide patients pain relief that are both effective and safe in an effort to decrease the amount of pain medication used.


Eligibility criteria:
inclusion criteria: * participants having a primary rotator cuff repair * age 18 and older * english speaking * ability to complete surveys by phone or in person * ability to provide informed consent exclusion criteria: * revision rotator cuff repair (rcr) cases * participants having an open rcr * allergies and/or medical contra-indications to study medications * non-english speakers * participants who are pregnant, plan to become pregnant and do not utilize adequate contraceptive means, or are currently breastfeeding (all patients who have the potential to be pregnant are administered a urine beta-hcg pregnancy test, with suspected false-positive or equivocal urine pregnancy tests followed by a more specific serum pregnancy test) * rotator cuff repair needing graft augmentation * known alcohol or narcotic abuse history * existing contract with a pain specialist due to underlying preoperative pain syndrome * preoperative opioid use within the 3 months prior to surgery
effect of simvastatin on sepsis and febrile neutropenia in patients with acute lymphoblastic leukemia

Conditions: Strains; Acute Lymphoblastic Leukemia; Sepsis

Summary: in general, the percentage of complete remissions is 85 - 90 % for acute lymphoid leukemia (all). in developing countries, percentages are lower secondary to higher sepsis-related mortality. although the effect of statins on inflammatory response associated with sepsis has been demonstrated, including an effect on bacterial proliferation in patients with a state of immunosuppression, their effect has not been demonstrated so far in patients with hemato-oncological cancer.

death associated with sepsis is one of the principal complications related to chemotherapy treatment; there are currently no strategies to prevent its development besides the use of prophylactic antibiotics or granulocyte colony stimulants to reduce the period of febrile neutropenia. most of the trials on the use of statins are retrospective with controversial results and include patients with different clinical situations that conditioned the septic study.

Eligibility criteria:
inclusion criteria: * patients diagnosed with acute leukemia under treatment of a chemotherapy regimen * stable performance status (ecog: 0 or karnofsky scale greater than 80%) at time of analysis and under chemotherapy regimen * life expectancy greater than 48 hours after diagnosis * oral route available * have signed informed consent at the time of the study * patients whose chemotherapy regimen is administered in a hospital rather than an outpatient manner exclusion criteria: * patients with acute leukemias over 55 years of age and with impaired functional status at the time of diagnosis * elevation of liver enzymes 3 times higher than the range established by the central laboratory * persistent kidney involvement despite having adequate hydration * pregnant patients * patients with peripheral neuropathy considered severe or disabling grade * patients with a history of psychiatric disorders or psychotic attacks * individuals who do not have the oral route available, who are maintained with a nasogastric tube, or who require support for the diagnosis through parenteral nutrition * patients undergoing peritoneal dialysis or hemodialysis treatment * patients with leukemia associated with down syndrome * patients under low-intensity chemotherapy regimen or palliative regimen * previous allergy to any statin component * patients with a history of liver failure (child-pugh stage b or c)

Keywords: acute lymphoblastic leukemia sepsis febrile neutropenia simvastatin